Loading clinical trials...
Loading clinical trials...
The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime after 12 weeks of treatment in patients with fibromyalgia. The use of low-dose sub...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Tonix Pharmaceuticals, Inc.
NCT07226648 · Fibromyalgia
NCT06672237 · Neuromuscular Disease, Neuromuscular Diseases (NMD), and more
NCT07358754 · Fibromyalgia
NCT06518278 · Osteoarthritis, Fibromyalgia, and more
NCT06923800 · Fibromyalgia, Irritable Bowel Syndrome
Birmingham, Alabama
Phoenix, Arizona
Oceanside, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions